Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
2
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
3
Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy
4
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
5
